Rhelion subsidiary Filament Health ships PEX010 psilocybin to University of Calgary for Phase 2 PTSD trial

Filament Health shipped PEX010 to the University of Calgary for the Phase 2 PsiPTSD study targeting adult survivors of intimate partner violence.